Customized RVG peptide-conjugated LNP development services for brain-targeted nucleic acid delivery, blood-brain barrier transport studies, neuronal uptake evaluation, ligand density optimization, and payload-compatible formulation screening.
RVG peptide-conjugated lipid nanoparticles are LNP delivery systems that display an RVG-derived peptide on the particle surface. The sequence used most often is RVG29, a 29-amino-acid fragment taken from the rabies virus glycoprotein. RVG29 interacts with nicotinic acetylcholine receptors, mainly the α7 subtype, which are present on neurons and on brain capillary endothelial cells. That receptor interaction is the reason RVG display is studied as a route for moving LNP cargo across the blood-brain barrier (BBB) and into neuronal cell populations.
BOC Sciences helps pharmaceutical and biotechnology teams build RVG-modified LNPs for siRNA, ASO, miRNA, mRNA, saRNA, circRNA, CRISPR components, proteins, peptides, small molecules, and imaging payloads. Our scope covers peptide design and lipid conjugate synthesis, surface functionalization, ligand density screening, physicochemical characterization, and BBB-relevant transport and neuronal delivery evaluation. We support brain-targeted LNP development programs with matched control particles, so results can be read with confidence instead of guesswork.
RVG Peptide-Conjugated Lipid Nanoparticles Schematic
We support the development cycle from RVG peptide selection to conjugated LNP preparation, physicochemical analysis, BBB-model transport testing, and functional delivery evaluation. Each work package is adapted to the intended payload and target cell model.
We select RVG29 constructs and prepare peptide-lipid building blocks with an attachment chemistry appropriate for the planned LNP surface.
RVG presentation is engineered alongside the surrounding PEG layer so that peptide accessibility can be compared without losing colloidal stability.
Peptide modification can alter lipid organization, RNA loading, and small-molecule retention. We optimize the core LNP and surface layer together.
Our analytical work distinguishes successful peptide attachment from particle changes that may compromise delivery.
We examine endothelial association, barrier passage, and activity in recipient neuronal cells as separate experimental questions.
We refine preparation and post-conjugation steps to make promising RVG-LNP candidates reproducible across research batches.
BOC Sciences supports different RVG peptide structures for LNP surface modification. Each design offers distinct conjugation characteristics and is selected according to the intended delivery application, formulation requirements, and targeting strategy.
Structural Features: A 29-amino-acid peptide derived from rabies virus glycoprotein, containing a receptor-interacting sequence associated with neuronal cell recognition.
Suitable Applications: Initial ligand screening, brain-targeting feasibility studies, and reference peptide selection for RVG-functionalized LNP development.
Structural Features: RVG29 containing an engineered terminal cysteine or accessible thiol group for conjugation with maleimide-functionalized lipids. Coupling-site selectivity requires consideration of the native cysteine residue.
Suitable Applications: Site-directed RVG surface conjugation, ligand density optimization, and preparation of RVG-LNPs for BBB transport and neuronal uptake studies.
Structural Features: RVG29 functionalized with azide or strained cycloalkyne groups, enabling selective copper-free click conjugation with complementary lipid components.
Suitable Applications: Modular RVG-LNP surface functionalization, controlled peptide attachment, and ligand modification of preformed LNPs under mild reaction conditions.
Structural Features: RVG29 connected to a phospholipid or other hydrophobic lipid anchor through a flexible PEG spacer, providing adjustable peptide exposure and surface presentation.
Suitable Applications: RVG-LNP co-assembly, post-insertion surface modification, PEG spacer screening, and formulation development for brain-directed RNA and small-molecule delivery.
There is no universally correct way to put RVG29 on an LNP. The route changes how much peptide ends up on the surface, how stable the particle stays, and how much payload survives the process. We typically screen more than one route in the same project, and this work sits within our broader nanoparticle conjugation services.
The RVG-lipid goes into the lipid mixture together with the ionizable lipid, helper lipid, cholesterol, and PEG-lipid, and the peptide is presented as the particle forms.
Peptide-lipid micelles are added to finished LNPs under controlled temperature and mixing. This route keeps the original loading step untouched.
A cysteine-modified RVG29 is reacted with maleimide groups on the particle surface. The reaction is selective and gives the peptide a consistent orientation.
Strain-promoted azide-alkyne cycloaddition attaches the peptide without a copper catalyst, which is useful when the payload is an RNA species.
Share your payload, targeting goals, and formulation requirements with BOC Sciences. Our experts can help select suitable RVG peptide structures and conjugation strategies, followed by custom synthesis, LNP formulation, and functional delivery evaluation.
RVG display gives LNP developers a small, defined, fully synthetic ligand that can be tuned at the chemical level. That is a practical advantage when the goal is to move cargo across a barrier that most particles never cross.
Receptor-Oriented Brain Endothelial Interaction
RVG29 recognizes the α7 nicotinic acetylcholine receptor, which is expressed on brain capillary endothelial cells as well as on neurons. This gives the particle a defined interaction partner at the vascular side of the BBB, rather than relying on non-specific adsorption. In in vitro BBB models, that usually shows up as a measurable increase in transcytosis signal, and the increase can be suppressed by α-bungarotoxin pre-incubation, which helps confirm that transport is receptor-associated.
Potential for Enhanced Neuronal Delivery
Because the same receptor is present on neuronal cells, RVG display can support a second step after barrier crossing: association with the target cell population itself. In practice, this is studied by comparing RVG-LNP against a non-targeted LNP and a scrambled-peptide control at matched payload dose, then reading uptake and functional output in the same cultures. The useful signal is not uptake alone, but the gap between uptake and downstream expression or silencing.
Tunable Peptide Presentation and Surface Properties
Ligand density, PEG spacer length, and anchor chain length are independent variables that can be adjusted without changing the payload or the core lipid system. A short spacer with high density behaves differently from a long spacer at low density, and the useful combination is model-dependent. Being able to screen these together is what turns RVG modification from a fixed recipe into a design parameter.
Adaptable Formulation for Different Payloads
RVG surface engineering is compatible with siRNA, ASO, mRNA, saRNA, circRNA, CRISPR components, proteins, peptides, small molecules, and imaging agents, as long as the loading chemistry and the surface chemistry are selected together. This lets a team move from one payload type to another without rebuilding the entire targeting concept each time.
The payload decides the loading strategy, and the loading strategy decides which surface route is workable. We match RVG surface engineering to the payload chemistry rather than forcing one fixed protocol. For RNA cargo, this builds on our experience in nucleic acids encapsulation in LNPs.
| Payload Type | Supported Uses & RVG-LNP Development Considerations | Request Information |
|---|---|---|
| RVG-LNP Development for siRNA | Used for neuronal transcript silencing, pathway validation, and comparison against non-targeted formulations. Development focuses on encapsulation recovery after modification, free RNA removal, ligand density, and silencing readouts measured against scrambled-peptide controls. See lipid nanoparticles for siRNA delivery. | Inquiry |
| RVG-LNP Development for mRNA and Reporter RNA | Supports reporter expression studies, protein expression analysis, and formulation comparison in neuronal and brain endothelial models. Work covers mRNA integrity, encapsulation efficiency, surface peptide exposure, and expression readouts at matched dose. See lipid nanoparticles for mRNA delivery. | Inquiry |
| RVG-LNP Development for ASO | Applicable to splice-modulation and transcript-reduction studies in CNS-related cell models. Attention is given to ASO leakage during conjugation or insertion, particle stability, and dose-dependent knockdown comparisons. See lipid nanoparticles for ASO delivery. | Inquiry |
| RVG-LNP Development for miRNA | Used for miRNA mimic or inhibitor delivery in neuronal and glial co-culture studies. Development considers payload stability, particle uniformity, and target-related readouts under matched control conditions. See lipid nanoparticles for miRNA delivery. | Inquiry |
| RVG-LNP Development for saRNA and circRNA | Fits RNA formats that place higher demands on payload protection and intracellular release. We evaluate lipid nanoparticles for saRNA delivery and lipid nanoparticles for circRNA delivery with RVG surface modification, stability testing, and cell-based expression analysis. | Inquiry |
| RVG-LNP Development for CRISPR Components | Supports gRNA/mRNA co-loading and lipid nanoparticles for CRISPR RNP delivery in CNS research models. Development addresses cargo ratio control, particle uniformity, and editing-related readouts with matched controls. | Inquiry |
| RVG-LNP Development for pDNA | Applicable to larger construct delivery where payload size changes assembly behavior. We adjust lipid composition and mixing conditions, then verify lipid nanoparticles for pDNA delivery performance with RVG surface display. | Inquiry |
| RVG-LNP Development for Protein and Peptide | Suitable for enzymes, binding proteins, antigenic proteins, and functional peptides used in CNS delivery research. Work focuses on mild loading conditions, aggregation control, activity retention, and RVG-dependent uptake evaluation, including protein encapsulation in LNPs and peptide encapsulation in LNPs. | Inquiry |
| RVG-LNP Development for Small Molecule | Designed for hydrophobic, amphiphilic, or ionizable small molecules used in neuronal or brain endothelial studies. Development considers drug-lipid compatibility, loading method, leakage control, and release behavior, supported by lipid nanoparticles for small molecule delivery. | Inquiry |
| RVG-LNP Development for Fluorescent and Imaging Payloads | Supports labeled RNA, labeled protein, and dye-loaded particles used to track uptake, intracellular fate, and tissue-level distribution. We can prepare fluorescent-labeled lipid nanoparticles with RVG surface modification for imaging-based comparison. | Inquiry |
| RVG-LNP Development for Co-Delivery Systems | Fits projects that combine two payloads, such as an RNA plus a small molecule, or a gRNA plus an mRNA. Development addresses loading sequence, ratio control, particle uniformity, and lipid nanoparticles for co-delivery performance under RVG surface display. | Inquiry |
| RVG-LNP Development for Custom Payload | Built for unusual payloads, multi-component systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, RVG modification route, particle stability, and delivery performance in the selected model. | Inquiry |
RVG-LNP projects tend to stall at predictable points: the peptide is attached but invisible to the receptor, the particle grows, the payload leaks, or uptake is high while function stays flat. We work through these with formulation and evaluation data instead of assumptions.
✔ Limited BBB Transport After RVG Modification
If transcytosis barely moves after modification, the ligand is often present but not accessible, or the dose window is wrong. We screen ligand density, PEG spacer length, and anchor type together, then confirm the result in a brain endothelial barrier model with TEER monitoring and a non-targeted control.
✔ Insufficient RVG Exposure and Receptor Accessibility
A PEG corona that is too long, or a PEG-lipid level that is too high, can bury the peptide. We vary spacer length against total PEG-lipid content and check the outcome with surface peptide quantification plus a receptor-blocking experiment, so exposure is measured rather than inferred.
✔ Particle Instability Following Peptide Conjugation
Extra PEG-lipid or a charged peptide can push size and PDI upward, and can shorten storage life. We rebalance the helper lipid, cholesterol, and PEG-lipid levels, then run stability checks under the storage conditions you plan to use, supported by lipid nanoparticle stability testing.
✔ Reduced RNA Encapsulation and Payload Stability
Surface modification steps can pull payload out of the particle or damage it. We adjust aqueous phase pH, payload input, and incubation time, then quantify encapsulation efficiency, free payload fraction, and RNA integrity before any candidate advances to cell work.
✔ High Cellular Uptake but Weak Functional Delivery
When particles enter cells but the payload does not act, the limiting step is usually endosomal release. We address this through LNP endosomal escape evaluation and LNP transfection troubleshooting services, combined with ionizable lipid rebalancing.
✔ Uncertain Receptor-Mediated Targeting Specificity
A signal increase is not proof of mechanism. We build the comparison set into the study: non-targeted LNP, scrambled-RVG LNP, receptor-blocking pre-treatment, and where relevant a cell model with low receptor expression, so the targeting claim can be defended.
BOC Sciences helps research teams work through ligand exposure, payload leakage, particle instability, BBB model design, neuronal uptake, and functional delivery readouts.
We start with the payload, the cell or tissue target, the route you plan to use, and the readout that will decide success. We also review what you already have: an established LNP composition, a peptide sequence, or only a target hypothesis. From there we agree on the peptide format, the attachment route, the ligand density range to screen, and the control particles that will be prepared alongside the candidates.
Peptide and lipid conjugate preparation runs in parallel with formulation work. We prepare a candidate set across the agreed variables, usually several ligand densities crossed with one or two attachment routes, and include a non-targeted LNP and a scrambled-peptide LNP in the same batch series. Preparation uses controlled mixing, and buffer exchange is handled under conditions chosen to limit payload loss.
All candidates go through the same panel: size, PDI, zeta potential, payload loading, payload integrity, and surface peptide level. Candidates that pass move into BBB model transport assays and uptake studies in neuronal and endothelial models, with receptor-blocking and scrambled-peptide controls included in the same run rather than added later.
We review the full data set with you and explain which variable drove the result, not just which candidate won. Where a candidate is close to target, we run a focused second round around the variable that mattered. The final report brings characterization, transport, uptake, and functional data together so your team can make a formulation decision without re-reading scattered files.
RVG-modified LNPs are used across CNS research programs where systemic access and cell-level delivery are both part of the problem. The sections below reflect the project types we see most often.
Share your payload, target cell population, and evaluation model. We will outline a practical RVG-LNP development route with the variables worth screening first.
Challenge: A neuroscience group was working with a poorly water-soluble neuroprotective small molecule (measured logP around 4) and wanted to deliver it into dopaminergic cell models used for an injury-related paradigm. Their first RVG29-LNP co-assembled RVG29-PEG2000-DSPE at 1.5 mol% into a standard four-component formulation. After modification the mean hydrodynamic size moved from about 78 nm to 138 nm, PDI rose to 0.28, and uptake in differentiated neuronal cell cultures was only about 1.2-fold over the unmodified LNP.
Diagnosis: Two problems were compounding each other. The RVG-lipid input sat above the useful window, so the additional PEG-lipid burden disturbed assembly. At the same time, the PEG2000 spacer at that ratio placed a portion of the peptide inside the PEG corona, where the receptor could not reach it.
Solution: We rebuilt the screen around three crossed variables: attachment route (co-assembly, post-insertion, and thiol-maleimide with Cys-RVG29), ligand density (0.2, 0.5, and 1.0 mol%), and total PEG-lipid content (1.0, 1.5, and 2.5 mol%). Nine candidates were prepared under the same mixing conditions and triaged on size, PDI, and encapsulation before any cell work. Surviving candidates went into a brain endothelial barrier transport assay (TEER held above 250 Ω·cm2) and uptake measurements in differentiated dopaminergic cultures, with α-bungarotoxin pre-incubation and a scrambled-RVG particle included in the same run.
Result: Post-insertion at 0.5 mol% RVG29-PEG2000-DSPE with 1.5 mol% total PEG-lipid gave the best balance: about 96 nm mean size, PDI 0.14, and encapsulation near 86%. Barrier-model transport was roughly 2.4-fold higher than the unmodified LNP, and α-bungarotoxin pre-incubation reduced the signal by about 60%, supporting receptor involvement. The client carried two candidates into the next stage of the program.
Challenge: A biotechnology team developing an antisense oligonucleotide against a neuronal transcript needed silencing in primary cortical neuron cultures. Their RVG29-LNP showed strong cell-associated fluorescence, yet target reduction was only about 25% at 100 nM, and encapsulation fell from 88% to 71% during surface modification.
Diagnosis: The oligonucleotide was leaking during the 37 °C post-insertion incubation. Of the material that was taken up, most remained colocalized with endosomal markers, which pointed to release rather than binding as the limiting step.
Solution: We moved the peptide into the lipid phase as a pre-conjugated RVG29-PEG-lipid at 0.3 mol%, which removed the incubation step entirely. The ionizable lipid was rebalanced toward a pKa near 6.4, the helper lipid ratio was adjusted, and the ethanol exposure window was shortened. In parallel we ran endosomal escape and intracellular localization analysis on the same candidates, alongside a scrambled-RVG particle and a non-targeted LNP at matched dose.
Result: The revised RVG-LNP held about 104 nm with PDI below 0.18 and encapsulation above 90%. Target transcript reduction reached about 65% at 100 nM, compared with roughly 28% for the non-targeted LNP and 32% for the scrambled-RVG control. The client selected one formulation and one control particle for the following stage, with the full comparison data set in hand.
Expertise Across Peptide Chemistry and LNP DevelopmentOur development approach connects RVG peptide synthesis, linker engineering, conjugate analysis, and LNP formulation so that changes to ligand structure can be evaluated together with particle and cargo performance.
Multiple Strategies for Precise RVG Surface PresentationWe assess co-assembly, post-insertion, and covalent attachment while tracking peptide accessibility, spacer behavior, and residual free ligand through targeted surface analysis.
Formulation Design Tailored to Different PayloadsRNA, ASOs, and small molecules differ in loading and release behavior. We build payload-specific screening strategies rather than transferring one RVG-LNP composition across unrelated cargos.
From BBB Transport Assessment to Neuronal FunctionWe connect barrier integrity, endothelial transport, neuronal uptake, and functional endpoints to help clients distinguish promising brain-directed delivery from nonspecific cell association.
Data-Driven Screening for Better Formulation DecisionsCandidate selection is based on comparable particle, peptide-display, cargo-retention, and biological datasets, with clearly stated trade-offs and follow-up experiments.
RVG29 is a 29-amino-acid peptide derived from rabies virus glycoprotein that has been investigated for its interactions with neurons and brain endothelial cells, including pathways associated with nicotinic acetylcholine receptors (nAChRs). Displaying RVG29 on the LNP surface may improve cellular association, uptake, and brain-directed delivery in selected experimental models. However, performance depends on receptor expression, peptide orientation, PEG shielding, lipid composition, and protein corona formation. Reliable evaluation therefore requires comparing RVG-LNPs with matched unmodified LNPs while assessing cellular uptake, BBB transport, and functional payload delivery separately. Receptor-related controls can help determine whether observed improvements are associated with RVG-mediated targeting.
Not necessarily. Increased uptake by brain endothelial cells indicates greater particle association or internalization but does not establish successful transport across the blood-brain barrier (BBB) or functional delivery to neurons. Reliable BBB evaluation should combine appropriate endothelial barrier models with measurements of barrier integrity, permeability, and transcellular transport. For example, Transwell-based systems can be used to monitor particle-associated or payload signals on both sides of the barrier. Matched unmodified LNPs, receptor competition studies, and neuronal functional assays provide additional evidence. These evaluations help distinguish productive transport from endothelial retention, surface adsorption, free-label artifacts, or nonspecific leakage through a compromised barrier.
The most suitable conjugation method depends on RVG peptide structure, available reactive groups, lipid composition, payload properties, and the desired surface ligand density. Co-assembly using preconjugated RVG-lipids allows peptide incorporation during particle formation, whereas RVG-PEG-lipid post-insertion enables modification of preformed LNPs. Thiol-maleimide coupling and copper-free click chemistry offer additional options for selective surface attachment when compatible functional groups are available. Each method presents different considerations regarding reaction conditions, peptide accessibility, conjugation stability, and payload retention. Comparing multiple strategies through coupling analysis, particle characterization, and functional delivery studies helps identify the most suitable approach for a particular RVG-LNP formulation.
Yes. BOC Sciences provides customized RVG peptide design, synthesis, lipid conjugation, and surface functionalization services based on each project's targeting objectives, payload properties, and formulation requirements. Our capabilities include developing RVG29 derivatives with cysteine, azide, or other suitable reactive groups, as well as exploring PEG spacer lengths and lipid anchoring structures. For projects without an established conjugation strategy, we can investigate co-assembly, post-insertion, and selective covalent coupling approaches. By combining peptide synthesis, conjugate characterization, formulation screening, and functional evaluation, BOC Sciences helps researchers select RVG structures and attachment methods that fit their intended LNP development applications.
BOC Sciences supports customized RVG-LNP evaluation programs covering physicochemical characterization, surface ligand assessment, BBB model studies, and functional cellular delivery testing. Analytical assessments may include particle size, polydispersity index, zeta potential, encapsulation efficiency, morphology, and formulation stability. Surface characterization examines RVG peptide incorporation and accessibility. For brain-directed delivery projects, we can design studies of brain endothelial uptake, barrier transport, neuronal uptake, and payload-specific functional activity using appropriate research models. Matched unmodified LNPs and receptor-related controls can also be incorporated. These results help clients identify formulation bottlenecks, compare candidate designs, and make informed decisions about further optimization and development.
